1. FEDERAL BUREAU OF PRISONSCLINICAL PRACTICE GUIDELINES FORTHE MANAGEMENT OF CORONARY ARTERY DISEASE SEPTEMBER, 2001PURPOSEThe Federal Bureau of Prisons Clinical Practice…

Slide 1 Slide 2 19 102 patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the…

1. Ivabradine inORIGINAL ARTICLEStable Coronary Artery Disease withoutClinical Heart FailureKim Fox et al,NEJM,Aug 31,2014 2. Does it Signify the benefit of Ivabradineor…

1. TOP IO 10 DIEAPOCA, ;PSE 2. With the power of a rhino,the speed oi a cheetah.you'll leave the undead in a cloud of dust or as a smear on the hood Just be careful…

Slide 1 Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med. 2014 August 31. DOI:10.1056/NEJMoa1406430. Slide 2 Ivabradine n=654 (3.03% PY) Placebo…

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med. 2014 August 31. DOI:10.1056/NEJMoa1406430. Ivabradine n=654 (3.03% PY) Placebo n=611 (2.82%…

19 102 patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG…

In patients with type 2 diabetes, are the clinical effects of TZDâs the same? The concept of Diabetes & CV risk: A lifetime risk challenge Vascular function as an early…